$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

$swtx Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000177342721000003 Filed on May 05, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.38M	$6.400M
YoY Change	93.44%	95.72%
% of Gross Profit
Research & Development	$17.38M	$9.727M
YoY Change	78.63%	15.52%
% of Gross Profit
Depreciation & Amortization	$110.0K	$70.00K
YoY Change	57.14%	250.0%
% of Gross Profit
Operating Expenses	$29.76M	$16.13M
YoY Change	84.48%	37.98%
Operating Profit	-$29.76M	-$16.13M
YoY Change	84.48%
Interest Expense	-$30.00K	$840.0K
YoY Change	-103.57%	200.0%
% of Operating Profit
Other Income/Expense, Net	$230.0K	$936.0K
YoY Change	-75.43%
Pretax Income	-$29.79M	-$15.29M
YoY Change	94.83%	34.01%
Income Tax
% Of Pretax Income
Net Earnings	-$29.79M	-$15.29M
YoY Change	94.76%	34.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$617.7K	-$355.5K
COMMON SHARES
Basic Shares Outstanding	48.23M shares
Diluted Shares Outstanding	48.23M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$477.4M	$311.1M
YoY Change	53.46%
Cash & Equivalents	$95.43M	$311.6M
Short-Term Investments	$382.0M
Other Short-Term Assets	$4.100M	$2.600M
YoY Change	57.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$481.5M	$313.6M
YoY Change	53.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.024M	$900.0K
YoY Change	13.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.610M	$900.0K
YoY Change	301.11%
Other Assets	$2.547M	$2.000M
YoY Change	27.35%
Total Long-Term Assets	$73.07M	$3.800M
YoY Change	1823.0%
TOTAL ASSETS
Total Short-Term Assets	$481.5M	$313.6M
Total Long-Term Assets	$73.07M	$3.800M
Total Assets	$554.6M	$317.4M
YoY Change	74.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.229M	$1.600M
YoY Change	39.31%
Accrued Expenses	$15.26M	$6.600M
YoY Change	131.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.200M
YoY Change
Total Short-Term Liabilities	$18.73M	$8.600M
YoY Change	117.78%
LONG-TERM LIABILITIES
Long-Term Debt	$1.000M	$0.00
YoY Change
Other Long-Term Liabilities	$131.0K	$700.0K
YoY Change	-81.29%
Total Long-Term Liabilities	$131.0K	$700.0K
YoY Change	-81.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.73M	$8.600M
Total Long-Term Liabilities	$131.0K	$700.0K
Total Liabilities	$19.89M	$9.300M
YoY Change	113.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$148.4M
YoY Change
Common Stock	$5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$534.7M	$308.1M
YoY Change
Total Liabilities & Shareholders Equity	$554.6M	$317.4M
YoY Change	74.73%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$29.79M	-$15.29M
YoY Change	94.76%	34.04%
Depreciation, Depletion And Amortization	$110.0K	$70.00K
YoY Change	57.14%	250.0%
Cash From Operating Activities	-$21.10M	-$16.40M
YoY Change	28.7%	128.38%
INVESTING ACTIVITIES
Capital Expenditures	$45.00K	$160.0K
YoY Change	-71.88%	-161.54%
Acquisitions
YoY Change
Other Investing Activities	-$30.87M
YoY Change
Cash From Investing Activities	-$30.92M	-$160.0K
YoY Change	19223.75%	-38.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$359.0K	$6.000K
YoY Change	5883.33%	-100.0%
NET CHANGE
Cash From Operating Activities	-$21.10M	-$16.40M
Cash From Investing Activities	-$30.92M	-$160.0K
Cash From Financing Activities	$359.0K	$6.000K
Net Change In Cash	-$51.66M	-$16.55M
YoY Change	212.13%	-110.58%
FREE CASH FLOW
Cash From Operating Activities	-$21.10M	-$16.40M
Capital Expenditures	$45.00K	$160.0K
Free Cash Flow	-$21.15M	-$16.56M
YoY Change	27.73%	139.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001773427
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-39044
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	SPRINGWORKS THERAPEUTICS, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-4066827
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49061125	shares
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Washington Blvd
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
CY2021Q1	dei	City Area Code CityAreaCode	203
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	883-9490
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	SWTX
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95426000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147089000	USD
CY2021Q1	us-gaap	Marketable Securities MarketableSecurities	381985000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	361395000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	4103000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	4914000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	481514000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	513398000	USD
CY2021Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	63631000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	53336000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1024000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1075000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1697000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1944000	USD
CY2021Q1	us-gaap	Equity Method Investments EquityMethodInvestments	3610000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	3871000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	565000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	565000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2547000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2002000	USD
CY2021Q1	us-gaap	Assets Assets	554588000	USD
CY2020Q4	us-gaap	Assets Assets	576191000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2229000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1350000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15256000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14885000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1244000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1375000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18729000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17610000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1031000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1359000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	131000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	164000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	19891000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19133000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49024152	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49024152	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48819591	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48819591	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	683029000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	675615000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	53000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	41000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148390000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118603000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	534697000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	557058000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	554588000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	576191000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17375000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9727000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12381000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6403000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	29756000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	16130000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29756000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16130000	USD
CY2021Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3000	USD
CY2020Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	227000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	936000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	936000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-261000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-100000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-15294000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.62
CY2020Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.37
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48229539	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41789120	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-15294000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29775000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15294000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	322072000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1350000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-15294000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	308134000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	557058000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7055000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	359000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	534697000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-29787000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-15294000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	110000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	70000	USD
CY2021Q1	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	257000	USD
CY2020Q1	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	263000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7055000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1350000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-261000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-100000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-697000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1142000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	545000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	281000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	879000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1037000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	357000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2358000	USD
CY2021Q1	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-355000	USD
CY2020Q1	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-353000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-33000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21104000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16398000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	160000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	86373000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	55500000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30918000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-160000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	359000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	359000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	328192000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-51663000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16552000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147654000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95991000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	311640000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SpringWorks Therapeutics, Inc., or the Company, was formed in Delaware on August 18, 2017.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $148.4 million and $118.6 million, and working capital of $462.8 million and $495.8 million, as of March 31, 2021 and December 31, 2020, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company’s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $541.0 million and $561.8 million as of March 31, 2021 and December 31, 2020, respectively. Based on the Company's cash, cash equivalents and marketable securities as of March 31, 2021, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2020, the World Health Organization designated the outbreak of the disease associated with the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The Company did not observe significant impacts on its business or results of operations for the periods presented due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company’s future results will depend on future developments, the pandemic and associated impacts could result in a material impact to the Company’s future financial condition, results of operations and cash flows.</span></div>
CY2021Q1	swtx	Number Of Clinical Trials NumberOfClinicalTrials	2	trial
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148400000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118600000	USD
CY2021Q1	swtx	Working Capital WorkingCapital	462800000	USD
CY2020Q4	swtx	Working Capital WorkingCapital	495800000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	541000000.0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	561800000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	445563000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	83000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	445616000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	414690000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	52000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	414731000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	889000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	827000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1920000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5834000	USD
CY2021Q1	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	11789000	USD
CY2020Q4	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	7922000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	658000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	302000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15256000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14885000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	916000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1297000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	135000	USD
CY2021Q1	swtx	Lessee Operating Lease Liability Payments Due After Two Year LesseeOperatingLeaseLiabilityPaymentsDueAfterTwoYear	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2348000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	73000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2275000	USD
CY2021Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6378341	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5486209	shares

Files In Submission

Name	View Source	Status
0001773427-21-000003-index-headers.html	Edgar Link	pending
0001773427-21-000003-index.html	Edgar Link	pending
0001773427-21-000003.txt	Edgar Link	pending
0001773427-21-000003-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
swtx-20210331.htm	Edgar Link	pending
swtx-20210331.xsd	Edgar Link	pending
swtx-20210331xex3111.htm	Edgar Link	pending
swtx-20210331xex3121.htm	Edgar Link	pending
swtx-20210331xex3211.htm	Edgar Link	pending
swtx-20210331xex3221.htm	Edgar Link	pending
swtx-20210331_cal.xml	Edgar Link	unprocessable
swtx-20210331_def.xml	Edgar Link	unprocessable
swtx-20210331_htm.xml	Edgar Link	completed
swtx-20210331_lab.xml	Edgar Link	unprocessable
swtx-20210331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

2021 Q1 Form 10-Q Financial Statement

#000177342721000003 Filed on May 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX SpringWorks Therapeutics, Inc. Stock $swtx

2021 Q1 Form 10-Q Financial Statement

#000177342721000003 Filed on May 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx